RSV clinical trials at University of California Health
4 in progress, 2 open to eligible people
EDP 938 Regimens in Children With RSV
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages up to 36 months
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
at UC Davis UCLA
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
open to eligible people ages up to 2 years
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
at UCSF
Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to <24 months.
at UCLA
Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
Sorry, in progress, not accepting new patients
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to <60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).
at UCLA
Our lead scientists for RSV research studies include Jaime Deville.
Last updated: